Drug Trial Radar · NCT07947121
A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Dec 25, 2026
Primary completion
Feb 24, 2031
Study completion Mar 24, 2032
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive type of lung cancer. Current treatment options are limited, and response to treatment may not last long. Outcomes are especially poor when the cancer has spread to the brain. This study tests whether a new treatment: risvutatug rezetecan (Ris-Rez) with atezolizumab works better than standard of care treatment. Ris-Rez is designed to deliver cancer-killing medicine directly to cancer cells. Atezolizumab helps the immune system attack cancer cells. Researchers will see if this combination helps people live longer and keeps the cancer from getting worse.
Conditions
- Lung Neoplasm
Interventions
Ris-RezBiological
Ris-Rez will be administered.
AtezolizumabBiological
Atezolizumab will be administered.
EtoposideDrug
Etoposide will be administered.
CarboplatinDrug
Carboplatin will be administered.
LurbinectedinDrug
Lurbinectedin will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to 50 months
- Progression-free survival (PFS) by Blinded independent central review (BICR) assessmentTime frame: Up to 50 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.